MHRAsafety guidance54% confidence
Regulation of AI in Healthcare
Source: MHRA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (cardiology) as Bayer.
Regulatory Analysis
The MHRA is seeking evidence on the regulation of AI in healthcare to inform the recommendations of the National Commission into the Regulation of AI in Healthcare.
Supporting Context
- Therapeutic area
- Cardiology · Pulmonary Hypertension
- Sub-indication
- Hypertension
Related signal: FDA Accepts Supplement for ADEMPAS (Riociguat) by Bayer Healthcare